Advagene Biopharma Co., Ltd.

As of June 30, 2026, Advagene Biopharma Co., Ltd. carries a market capitalization of 1.70B, placing it among publicly traded companies globally. Its enterprise value stands at 1.38B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Advagene Biopharma Co., Ltd. has 69.38M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Advagene Biopharma Co., Ltd. maintains a current ratio of 44.32, meaning it holds 44.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Advagene Biopharma Co., Ltd.'s stock has declined approximately 33.28% over the past 52 weeks. The 50-day moving average sits at 24.70, while the 200-day moving average is 26.51.

As of June 30, 2026, Advagene Biopharma Co., Ltd. holds 325.18M in cash and equivalents against 3.73M in total debt, resulting in a net debt position of -264.08M. Total book value stands at 356.43M, with working capital of 343.51M providing operational flexibility.

Advagene Biopharma Co., Ltd.'s most recent stock split took place on April 9, 2026 with a 204:205 split ratio.